Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636250 | 0.98 | KDM4E (0.46) | ALDH1A1KDM4EMAPTALOX15GAA | |
| SCHEMBL1515138 | 0.93 | — | — | |
| SCHEMBL303623 | 0.88 | — | — | |
| SCHEMBL11154948 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL10667343 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL5120555 | 0.79 | TSHR (0.50) | ALDH1A1MAPK1HPGDHSD17B10TSHR | |
| SCHEMBL234027 | 0.79 | KDM4E (0.55) | ALDH1A1KDM4EMAPTALOX15GAA | |
| SCHEMBL73853 | 0.78 | KDM4E (0.46) | ALDH1A1KDM4EMAPTALOX15GAA | |
| SCHEMBL6586283 | 0.78 | CYP1A2 (0.41) | ALDH1A1KDM4EMAPTALOX15GAA | |
| SCHEMBL8480122 | 0.77 | KDM4E (0.48) | ALDH1A1KDM4EMAPTALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102365273-A | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof | SANOFI AVENTIS | 2012-02-29 | — | — | CN | claimed |
| US-20230110603-A1 | 3-ALKOXYBENZAMIDE DERIVATIVE, AND PEST CONTROL AGENT | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2023-04-13 | — | — | US | disclosed |
| CN-109996792-B | Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain | 赫普泰雅治疗有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-4098650-A1 | 3-ALKOXY BENZOIC ACID AMIDE DERIVATIVE, AND PEST CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2022-12-07 | — | — | EP | disclosed |
| CN-115052856-A | 3-alkoxybenzamide derivative and pest control agent | 组合化学工业株式会社 | 2022-09-13 | — | — | CN | disclosed |
| WO-2021153720-A1 | 3-ALKOXY BENZOIC ACID AMIDE DERIVATIVE, AND PEST CONTROL AGENT | クミアイ化学工業株式会社 | 2021-08-05 | — | — | WO | disclosed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-105829307-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3080127-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| WO-1997009319-A1 | SUBSTITUTED 1-AMINO-3-PHENYLURACIL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-03-13 | — | — | WO | disclosed |
| WO-1997001541-A1 | SUBSTITUTED CYANOPHENYL URACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| CN-1057269-A | Peptide compounds and preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-12-25 | — | — | CN | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-4845223-A | FLUORESCENT PERYLENE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| US-4396620-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-3932423-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES (JA) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110603-A1 | 3-ALKOXYBENZAMIDE DERIVATIVE, AND PEST CONTROL AGENT | CBR3, ALK, BRS3 | ALDH1A1 1088/4885KDM4E 782/4885MAPT 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.